Home
October 2009 November 2009 December 2009
Su Mo Tu We Th Fr Sa
Week 45 1 2 3 4 5 6 7
Week 46 8 9 10 11 12 13 14
Week 47 15 16 17 18 19 20 21
Week 48 22 23 24 25 26 27 28
Week 49 29 30

David P. Wood, MD

Dr. Wood is a graduate of the University of Michigan Medical School in 1983. He subsequently was a Urology resident at the Cleveland Clinic and then a clinical and research fellow at Memorial Sloan Kettering Cancer Center. During this fellowship program, he developed an active basic science laboratory evaluating circulating prostate cancer cells. Dr. Wood then became Assistant Professor and Chief of Urologic Oncology at the University of Kentucky. There he received NIH funding for his work in circulating prostate cancer cells and developed an active clinical trials-based urologic oncology program. In 1996, he moved to the newly formed Karmanos Cancer Institute at Wayne State University where he became Professor of Urology and Program Leader of the Prostate Cancer Program in the Cancer Center. He continued his research and began developing an active clinical trials based research program evaluating novel agents before radical prostatectomy or radical cystectomy. In 2002, he moved to the University of Michigan to be Chief of Urologic Oncology in the Department of Urology. There he actively oversees the Combined Minimally Invasive Fellowship Program that includes 1 ½ years of clinical and 1 ½ years of research activities.

Dr. Wood is active in the American Board of Urology and the American Urological Association participating in many AUA courses and plenary sessions. He has also served on the Qualifying Exam Committee. He is on the editorial board of the Journal of Urology and is a peer review expert for many of the top urological journals. Dr. Wood continues his grant funding through the National Cancer Institute and is co-director of the annual Winter Urological Forum. He is head of the local bladder committee in the Southwest Oncology Group GU program.

Dr. Wood is an active clinical who participates in numerous clinical trials to develop improvements in the quality of care in patients with urologic cancers.

Member's Section

Login

Sign Up

Quick Search